<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/etm.2017.5637</article-id>
<article-id pub-id-type="publisher-id">ETM-0-0-5637</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Berbamine induces SMMC-7721 cell apoptosis via upregulating p53, downregulating survivin expression and activating mitochondria signaling pathway</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Cao</surname><given-names>Ying</given-names></name>
<xref rid="af1-etm-0-0-5637" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Cao</surname><given-names>Jianbo</given-names></name>
<xref rid="af1-etm-0-0-5637" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yu</surname><given-names>Binbin</given-names></name>
<xref rid="af1-etm-0-0-5637" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Shusheng</given-names></name>
<xref rid="af2-etm-0-0-5637" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Lili</given-names></name>
<xref rid="af1-etm-0-0-5637" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Tao</surname><given-names>Li</given-names></name>
<xref rid="af1-etm-0-0-5637" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Sun</surname><given-names>Wanping</given-names></name>
<xref rid="af3-etm-0-0-5637" ref-type="aff">3</xref>
<xref rid="c1-etm-0-0-5637" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-etm-0-0-5637"><label>1</label>Department of Pharmacy, Zhangjiagang Hospital Affiliated to Soochow University, Zhangjiagang, Jiangsu 215600, P.R. China</aff>
<aff id="af2-etm-0-0-5637"><label>2</label>Department of Surgery, Zhangjiagang Hospital Affiliated to Soochow University, Zhangjiagang, Jiangsu 215600, P.R. China</aff>
<aff id="af3-etm-0-0-5637"><label>3</label>Laboratory of Molecular Diagnostics, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, P.R. China</aff>
<author-notes>
<corresp id="c1-etm-0-0-5637"><italic>Correspondence to</italic>: Dr Wanping Sun, Laboratory of Molecular Diagnostics, College of Pharmaceutical Sciences, Soochow University, 199 Renai Road, Suzhou, Jiangsu 215123, P.R. China, E-mail: <email>sunwppeeing@hainan.net</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>02</month>
<year>2018</year></pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>12</month>
<year>2017</year></pub-date>
<volume>15</volume>
<issue>2</issue>
<fpage>1894</fpage>
<lpage>1901</lpage>
<history>
<date date-type="received"><day>27</day><month>04</month><year>2017</year></date>
<date date-type="accepted"><day>22</day><month>11</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Cao et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Hepatocellular carcinoma (HCC) is a primary malignancy in the liver, which is a global health problem. The present study aimed to observe the apoptotic effects of berbamine on SMMC-7721 cell lines and to investigate the effects of berbamine on induction of the intrinsic apoptotic pathway. The human HCC SMMC-7721 cells were cultured and cell morphology observed using a phase contrast microscope. SMMC-7721 cell apoptosis was examined by employing a flow cytometry assay. The nuclei of SMMC-7721 cells were stained with DAPI and observed by utilizing a laser fluorescence microscope. Cytochrome <italic>c</italic> (Cyto <italic>c</italic>) levels were evaluated by using immunofluorescence staining. The reverse transcription-semi-quantitative polymerase chain reaction (RT-sqPCR) and western blot analysis were used to examine the mRNA and protein levels of B-cell lymphoma 2, (Bcl-2), Bax, Bcl-2-associated X, apoptosis regulator, p53 and survivin, respectively. Berbamine inhibited SMMC-7721 cell growth at 20 and 0 &#x00B5;mol/l, compared with control group (0 &#x00B5;mol/l berbamine). DAPI results demonstrated that berbamine affected the nucleus morphology of SMMC-7721 cells. Berbamine at a concentration of 20 &#x00B5;mol/l (P&#x003C;0.05) and 40 &#x00B5;mol/l (P&#x003C;0.01) significantly enhanced apoptosis rate compared with control group. Berbamine triggered Cyto <italic>c</italic> release from SMMC-7721 cell nuclei to the cytoplasm. Berbamine (10, 20, 40 &#x00B5;mol/l) significantly enhanced Bax and p53 levels and decreased Bcl-2 and survivin levels compared with control group, according to RT-sqPCR and western blot assay findings. In conclusion, berbamine induced SMMC-7721 cell apoptosis, through upregulating p53 expression and downregulating survivin expression, which further triggered mitochondria signaling pathway-mediated apoptosis.</p>
</abstract>
<kwd-group>
<kwd>hepatocellular carcinoma</kwd>
<kwd>SMMC-7721</kwd>
<kwd>berbamine</kwd>
<kwd>apoptosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hepatocellular carcinoma (HCC) is a kind of primary malignancy in the liver, which is a global health problem, and characterizes with higher mortality and morbidity rates (<xref rid="b1-etm-0-0-5637" ref-type="bibr">1</xref>&#x2013;<xref rid="b3-etm-0-0-5637" ref-type="bibr">3</xref>). The HCC is the 5th most prevalent type of cancer and the 3rd leading reason for the higher cancer-associated mortality all over the world (<xref rid="b2-etm-0-0-5637" ref-type="bibr">2</xref>,<xref rid="b4-etm-0-0-5637" ref-type="bibr">4</xref>). In the worldwide, there are ~650,000 HCC cases were reported annually, in which 75&#x2013;80&#x0025; distributes in the Asian countries, and 55&#x0025; distributes in China (<xref rid="b5-etm-0-0-5637" ref-type="bibr">5</xref>,<xref rid="b6-etm-0-0-5637" ref-type="bibr">6</xref>). Meanwhile, in China, the HCC has become the second leading cause for the cancer-related mortality (<xref rid="b7-etm-0-0-5637" ref-type="bibr">7</xref>). Nowadays, the chemotherapetic treatment is the most common and efficacy strategy for HCC therapy, however, a series of side-effects, such as the drug resistance and the toxicity, limit the application in clinics (<xref rid="b8-etm-0-0-5637" ref-type="bibr">8</xref>). Therefore, attempting to discover a kind of effective chemotherapeutic agent is urgent and critical for the HCC therapy.</p>
<p>In recent years, many traditional Chinese medicine has been studied and a few of effective and safe antitumor compounds have been screened (<xref rid="b9-etm-0-0-5637" ref-type="bibr">9</xref>). Berbamine is one of the active components that extracted from the <italic>Berberis amurensis</italic>, a traditional Chinese medicine, which is a kind of alkaloid (<xref rid="b10-etm-0-0-5637" ref-type="bibr">10</xref>). The berbamine is crystallized and it&#x0027;s structure (molecular formula: C<sub>37</sub>H<sub>48</sub>N<sub>2</sub>O<sub>6</sub>&#x00B7;2HCl) has been revealed in the past years (<xref rid="b10-etm-0-0-5637" ref-type="bibr">10</xref>). The berbamine has been applied for centuries, to treat the inflammatory diseases and the other disorders (<xref rid="b11-etm-0-0-5637" ref-type="bibr">11</xref>&#x2013;<xref rid="b21-etm-0-0-5637" ref-type="bibr">21</xref>). The natural compounds and their associated derivatives of the traditional Chinese medicine are the promising candidates for the anticancer drugs (<xref rid="b15-etm-0-0-5637" ref-type="bibr">15</xref>,<xref rid="b16-etm-0-0-5637" ref-type="bibr">16</xref>). Actually, a large number of the phytochemicals characterize with anticancer effects in many cancer model in both <italic>in vivo</italic> and <italic>in vitro</italic> levels (<xref rid="b17-etm-0-0-5637" ref-type="bibr">17</xref>). In recent years, many reported that the berbamine could inhibit proliferation of plenty tumors <italic>in vitro</italic> levels, including breast cancer, non-small cell lung cancer (NSCLC), multiple myeloma and the leukaemia (<xref rid="b18-etm-0-0-5637" ref-type="bibr">18</xref>&#x2013;<xref rid="b21-etm-0-0-5637" ref-type="bibr">21</xref>). Especially, the berbamine could significantly inhibit the proliferation of the durg-resistant leukemia <italic>in vivo</italic> (<xref rid="b22-etm-0-0-5637" ref-type="bibr">22</xref>). Moreover, the berbamine could also therapy the imatinib-resistant chronic myeloid leukemia effectively according to a clinical research (<xref rid="b23-etm-0-0-5637" ref-type="bibr">23</xref>).</p>
<p>To the best of our knowledge, there are only a few studies (<xref rid="b15-etm-0-0-5637" ref-type="bibr">15</xref>,<xref rid="b24-etm-0-0-5637" ref-type="bibr">24</xref>,<xref rid="b25-etm-0-0-5637" ref-type="bibr">25</xref>) investigating the effects of berbamine on the human HCC. Therefore, further researches are required and necessary to investigate the biological function and protective roles of berbamine in HCC. In the present study, the hepatocarcinoma cell, SMMC-7721 was used, which is a commonly used representative HCC cell line according to the previous studies (<xref rid="b6-etm-0-0-5637" ref-type="bibr">6</xref>,<xref rid="b15-etm-0-0-5637" ref-type="bibr">15</xref>,<xref rid="b16-etm-0-0-5637" ref-type="bibr">16</xref>). The SMMC-7721 was treated <italic>in vitro</italic> with the berbamine at different concentrations. This study aims to observe the apoptotic effects of berbamine on SMMC-7721 cell lines and to investigate the effects of berbamine on induction of intrinsic apoptotic pathway.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture of SMMC-7721</title>
<p>The human normal hepatocyte and the human HCC cell line, SMMC-7721, were purchased from the Cell Bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The SMMC-7721 cells were cultured in the Dulbecco&#x0027;s modified Eagle&#x0027;s medium (DMEM) containing 100 &#x00B5;g/ml streptomycin sulfate, 100 U/ml penicillin and 10&#x0025; fetal bovine serum (FBS) (all from Gibco-BRL, Grand Island, NY, USA). The SMMC-7721 cells were incubated in a humidified incubator (Thermo Electron Corporation, Waltham, MA, USA) and 5&#x0025; CO<sub>2</sub> atmosphere at 37&#x00B0;C. The SMMC-7721 cells were detached from the cell plates by utilizing the 0.25&#x0025; trypsin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 3 min when the cells growing to near confluence.</p>
</sec>
<sec>
<title>Cytotoxicity on cells (MTT assay) and IC50</title>
<p>The MTT assay was employed to examine the cytotoxicity (IC<sub>50</sub>) or the cell viability. Briefly, the normal hepatocyte and the SMMC-7721 were placed within the 96-well culture plates at a density of 5&#x00D7;10<sup>3</sup> cells/well in 200 &#x00B5;l medium at 37&#x00B0;C for 24 h. Total of 20 &#x00B5;l of MTT solution (5 mg/ml; Sigma-Aldrich; Merck KGaA) was added to the 96-well plates, and cultured for 4 h. Then, the supernatant was discarded and the DMSO was added (150 &#x00B5;l/well; Sigma-Aldrich; Merck KGaA). The absorbance was measured by using a Universal microplate reader (SpectraMax Plus 384; Molecular Devices, LLC, Sunnyvale, CA, USA) at the wavelength of 570 nm. The cytotoxicity of normal hepatocyte of SMMC-7721 cells was illustrated as IC<sub>50</sub> (concentration of 50&#x0025; cytotoxicity, which was extrapolated form the linear regression analysis of experimental findings).</p>
</sec>
<sec>
<title>Cell morphology observation</title>
<p>The SMMC-7721 cells were added to the DMEM medium and the cell concentration was adjusted to 1&#x00D7;10<sup>5</sup> cells/ml, and the cell were seeded into the 6-wells plate (2 ml/well). The cells were cultured for 24 h, and then treated with the different concentration of crystallized berbamine (10, 20 and 40 &#x00B5;mol/l, cat. no. 6078-17-7; Shanghai Standard Technology Co., Ltd., Shanghai, China) for another 24 h. The berbamine at the concentration of 0 &#x00B5;mol/l was considered as control group (without berbamine treatment, and only with DMEM). The cell morphology was observed and photographed by employing the phase contrast microscope.</p>
</sec>
<sec>
<title>Apoptosis examination</title>
<p>SMMC-7721 cells apoptosis was examined by employing FITC-Annexin V/PI cell apoptosis kit (cat. no. C1062; Beyotime Biological Technology Co., Ltd., Shanghai, China) due to the manufacturer&#x0027;s instructions. The SMMC-7721 cells were harvested by utilizing 0.25&#x0025; trypsin, and rinsed the PBS for three times, then cells were suspended in the 500 &#x00B5;l binding buffer. The suspended SMMC-7721 cells were treated with Annexin V-FITC (5 &#x00B5;l) at 4&#x00B0;C for 10 min. Then, SMMC-7721 cells were treated with 7-ADD solution (10 &#x00B5;l) at 4&#x00B0;C for 5 min. Finally, SMMC-7721 cell apoptosis was evaluated by using FACS flow cytometer (BD Biosciences Inc., Franklin Lakes, NJ, USA).</p>
</sec>
<sec>
<title>DAPI staining</title>
<p>The cover glasses were embedded into the 6-well plates, and the SMMC-7721 cells were added for culturing 4 h. Then, the different concentrations of berbamine (0, 10, 20 and 40 &#x00B5;mol/l) were added into the culture medium. Total of 48 h later, the SMMC-7721 cells were fixed with the 4&#x0025; paraformaldehyde for 15 min and subsequently incubated with the LysoTracker (red) at 37&#x00B0;C for 30 min. The cells were then washed by using the PBS for 3 times, and the nuclei were counter-stained by using the 4&#x2032;-6-diamidino-2-phenylindole (DAPI; Roche Diagnostics, Basel, Switzerland). The fluorescent images were observed by utilizing a laser fluorescence microscope (Olympus, Tokyo, Japan).</p>
</sec>
<sec>
<title>Immunofluorescence staining for cytochrome c (Cyto c)</title>
<p>The treatment for cells were performed according to the processes of &#x2018;DAPI staining&#x2019; section. After the PBS washing, the SMMC-7721 cells were incubated by using the 5&#x0025; BSA (Gibco-BRL) for 0.5 h, and washed with PBS for 3 times. Then, the cells were incubated with the rabbit anti-human Cyto <italic>c</italic> monoclonal antibody (cat. no. ab133504, 1:1,000; Abcam, Cambridge, MA, USA) at room temperature for 2 h. Then, the cells were washed with the PBS for 3 times, and 5 min per time. The cells were incubated with the FITC-conjugated goat anti-rabbit IgG (cat. no. ab6717, 1:2,000; Abcam) at room temperature for 1 h in dark. Finally, the cells were re-stained by using the DAPI for 10 min, and mounting. The fluorescent images were observed by using a fluorescence microscope (Olympus).</p>
</sec>
<sec>
<title>Reverse transcription-semi-quantitative polymerase chain reaction (RT-sqPCR)</title>
<p>Total cellular RNAs were extracted by utilizing RNAsimple Total RNA kit (Sigma-Aldrich; Merck KGaA). Then, the First-Strand cDNA Synthesis kit (Invitrogen Life Technologies, Carlsbad, CA, USA) was used to synthesize cDNA due to manufacturer&#x0027;s instructions. Then, the synthesized cDNA was used to amplify the target genes by utilizing PCR assay under the following conditions: 95&#x00B0;C for 4 min, following with 30 cycles of 94&#x00B0;C for 30 sec, 55&#x00B0;C for 30 sec, 72&#x00B0;C for 30 sec, and terminated with 72&#x00B0;C for 10 min. The primers for Bcl-2, Bax, p53, survivin and GAPDH (synthesized by Western Biotechnology Inc., Chongqing, China) were listed in <xref rid="tI-etm-0-0-5637" ref-type="table">Table I</xref>. Finally, the amplified products were loaded onto 1.5&#x0025; agarose gels, and the images were digitally captured by using the camera and analyzed with the image analysis software.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>The SMMC-7721 cells were lysed with the lysis buffer. The lysis products were separated by using the 15&#x0025; SDS-PAGE and the total proteins in the gels were electro-transferred onto PVDF membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were blocked with the 5&#x0025; defatted milk in the PBS supplementing with 0.05&#x0025; Tween-20 at 4&#x00B0;C for 1 h. The membranes were incubated with the rabbit anti-human Bcl-2 monoclonal antibody (cat. no. ab31124, 1:3,000) and mouse anti-human Bax monoclonal antibody (cat. no. ab77566, 1:3,000), rabbit anti-human survivin polyclonal antibody (cat. no. ab469, 1:2,000) (all from Abcam), mouse anti-human p53 monoclonal antibody (cat. no. 554167, 1:3,000; BD Biosciences Inc.) and rabbit anti-human GAPDH polyclonal antibody (cat. no. ab9385, 1:2,000; Abcam) at 4&#x00B0;C overnight. Then, the membranes were incubated with the horseradish peroxidase (HRP)-conjugated goat anti-rabbit (cat. no. ab6721, 1:2,000) and HRP-conjugated goat anti-mouse (cat. no. ab6789, 1:2,000) (both from Abcam) at room temperature for 1.5 h. The western blot bands were visualized by using the TMB color liquid (PE Applied Biosystems, Foster City, CA, USA).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The data were analyzed by using the SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). The data were illustrated as the mean &#x00B1; standard deviation. The comparisons among multiple groups were analyzed by using the ANOVA test followed by the Tukey&#x0027;s post host test. The comparisons between two groups were analyzed by using the Student&#x0027;s t-test. P-value &#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Berbamine exhibits no significant cytotoxic potential to normal hepatocyte</title>
<p>In order to confirm the cytotoxic potential of berbamine to the normal hepatocyte, the IC<sub>50</sub> was examined, and the MTT assay was also performed in this study. The results indicated that the IC<sub>50</sub> value in normal hepatocyte group (5670.94 &#x00B5;mol/l) was higher significantly compared to the SMMC-7721 group (35.48 &#x00B5;mol/l) (<xref rid="f1-etm-0-0-5637" ref-type="fig">Fig. 1A</xref>; P&#x003C;0.001). The MTT assay also showed that the there were even not cytotoxic effects of berbamine on the cell viability of normal hepatocyte at different concentrations (<xref rid="f1-etm-0-0-5637" ref-type="fig">Fig. 1B</xref>). However, the cell viability of SMMC-7721 group was significantly decreased following with the increased concentration of berbamine (<xref rid="f1-etm-0-0-5637" ref-type="fig">Fig. 1B</xref>; all P&#x003C;0.05).</p>
</sec>
<sec>
<title>Berbamine inhibits SMMC-7721 cells growth</title>
<p>According to the cell morphology, the SMMC-7721 cells in control group grew well, and formed the fusion colony cells (<xref rid="f2-etm-0-0-5637" ref-type="fig">Fig. 2A</xref>). However, following the increased concentration of berbamine (from 10 to 40 &#x00B5;mol/l), the SMMC-7721 cell amounts were obviously decreased (<xref rid="f2-etm-0-0-5637" ref-type="fig">Fig. 2B-D</xref>). Meanwhile, the SMMC-7721 cells in Control group were pleomorphic, and SMMC-7721 cells in other group were round or elliptical (<xref rid="f2-etm-0-0-5637" ref-type="fig">Fig. 2</xref>). Moreover, some of the cells also suspended in the medium in 20 and 40 &#x00B5;mol/l berbamine group. These results suggest that the berbamine obviously inhibited the SMMC-7721 cells growth.</p>
</sec>
<sec>
<title>Berbamine affects nucleus morphology</title>
<p>The SMMC-7721 cells were stained with DAPI and observed under the microscope. The results indicated that the cells illustrated the normal cell morphology and the nucleus were round and stained homogeneously in control group (<xref rid="f3-etm-0-0-5637" ref-type="fig">Fig. 3A</xref>). The nucleus were narrowed and deeply stained 48 h post the 10 &#x00B5;mol/l berbamine treatment (<xref rid="f3-etm-0-0-5637" ref-type="fig">Fig. 3B</xref>). In 20 &#x00B5;mol/l berbamine treatment group, we found the deeply stained nucleus, chromatin condensation in most SMMC-7721 cells (<xref rid="f3-etm-0-0-5637" ref-type="fig">Fig. 3C</xref>). However, the nucleus illustrated as strong fluorescence staining, fragmentary and polymorphonuclear in 40 &#x00B5;mol/l berbamine treatment (<xref rid="f3-etm-0-0-5637" ref-type="fig">Fig. 3D</xref>). The nucleus in <xref rid="f3-etm-0-0-5637" ref-type="fig">Fig. 3B-D</xref> illustrated the classical apoptotic morphology.</p>
</sec>
<sec>
<title>Berbamine induces SMMC-7721 cells apoptosis</title>
<p>Forty-eight hours post the berbamine treatment, the SMMC-7721 cells were stained with the Annexin V/PI. The results indicated that the berbamine (10 &#x00B5;mol/l) increased the apoptosis rate, however, no significant difference was discovered compared to Control group (<xref rid="f4-etm-0-0-5637" ref-type="fig">Fig. 4A and B</xref>, P&#x003E;0.05). The berbamine at concentration of 20 &#x00B5;mol/l (P&#x003C;0.05) and 40 &#x00B5;mol/l (P&#x003C;0.01) significantly enhanced the apoptosis rate compared to the Control group, respectively (<xref rid="f4-etm-0-0-5637" ref-type="fig">Fig. 4A, C and D</xref>).</p>
</sec>
<sec>
<title>Berbamine triggers Cyto c release from SMMC-7721 nucleus</title>
<p>The immunofluorescence staining was used to examine the Cyto <italic>c</italic> release from the SMMC-7721 nucleus. The results indicated that the Cyto <italic>c</italic> was slightly stained in the control group (<xref rid="f5-etm-0-0-5637" ref-type="fig">Fig. 5</xref>), and which mainly distributed in the nucleus. However, the staining of Cyto <italic>c</italic> in berbamine treatment was significantly strengthened in 20 and 40 &#x00B5;mol/l compared to control group (<xref rid="f5-etm-0-0-5637" ref-type="fig">Fig. 5</xref>), and the Cyto <italic>c</italic> was transferred from the nucleus to the cytoplasm.</p>
</sec>
<sec>
<title>Berbamine enhances Bax and p53 levels and decreases Bcl-2 and survivin levels</title>
<p>In this study, four apoptosis associated biomarkers, including Bax, Bcl-2, p53 and survivin, were examined by using both of RT-sqPCR and western blot analysis. The RT-sqPCR results showed that the Bax and p53 mRNA levels were significantly increased in 10, 20 and 40 &#x00B5;mol/l berbamine treatment group compared to control group (<xref rid="f6-etm-0-0-5637" ref-type="fig">Fig. 6</xref>; P&#x003C;0.05). Meanwhile, the Bcl-2 and survivin mRNA levels were significantly decreased in 10, 20 and 40 &#x00B5;mol/l berbamine treatment group compared to control group (<xref rid="f6-etm-0-0-5637" ref-type="fig">Fig. 6</xref>; P&#x003C;0.05).</p>
<p>Moreover, the western blot assay also showed that the Bax and p53 protein levels were significantly increased, and Bcl-2 and survivin protein levels were significantly decreased in 10, 20 and 40 &#x00B5;mol/l berbamine treatment group compared to control group (<xref rid="f7-etm-0-0-5637" ref-type="fig">Fig. 7</xref>; P&#x003C;0.05).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Although the berbamine has been extensively applied for many cancer treatment, however, the anticancer role of berbamine in HCC therapy has not been fully investigated. In this study, we studied the anticancer effects of berbamine on the SMMC-7721 cells proliferation and apoptosis.</p>
<p>Anti-apoptosis is the typical characteristic for the cancer cells, therefore, induction of cancer cell apoptosis is a key end for developing antitumor drugs (<xref rid="b26-etm-0-0-5637" ref-type="bibr">26</xref>). Therefore, this study observed the nucleus morphology of the SMMC-7721 cells, and the nucleus illustrated as fragmentary and polymorphonuclear in 20, 40 &#x00B5;mol/l berbamine treatment, which suggests that the classical apoptotic morphology was appeared in the berbamine treatment cells. Meanwhile, the apoptosis rate was also evaluated by using the flow cytometry assay, and results revealed that berbamine at concentration of 20 and 40 &#x00B5;mol/l significantly induced apoptosis compared to the control group, which suggests that berbamine processes the function of anti-apoptosis in SMMC-7721 cells, and is consistent with previous study (<xref rid="b19-etm-0-0-5637" ref-type="bibr">19</xref>,<xref rid="b27-etm-0-0-5637" ref-type="bibr">27</xref>).</p>
<p>The cell apoptosis mainly includes endogenous apoptosis and exogenous apoptosis, and the mitochondira-associated apoptosis is the key process for endogenous apoptosis. For the mitochondria-associated apoptosis, the Cyto <italic>c</italic> transferred from the nuclues to mitochondria and cytoplasm, and the Bcl-2 protein family plays an important role in the whole apoptotic processes (<xref rid="b28-etm-0-0-5637" ref-type="bibr">28</xref>). Our result indicated that Cyto <italic>c</italic> levels in berbamine treatment was significantly increased in 20 and 40 &#x00B5;mol/l compared to control group, which suggest that the Cyto <italic>c</italic> was transferred from the nucleus to the cytoplasm and mitochondria, and induced the apoptosis. Among the Bcl-2 family proteins, the Bcl-2 belongs to the anti-apoptotic protein and Bax belongs to the pro-apoptotic protein (<xref rid="b29-etm-0-0-5637" ref-type="bibr">29</xref>), both of which regulate the activity of the caspase protein and induce the cascade cell apoptosis (<xref rid="b30-etm-0-0-5637" ref-type="bibr">30</xref>). In our study, berbamine significantly enhanced Bax levels and decreased Bcl-2 levels compared to the un-treated with berbamine group, which suggests that the apoptosis of SMMC-7721 was triggered by the mitochondria-associated signaling pathway.</p>
<p>p53 is the most common antitumor gene of 20 kb, which includes 11 exons and 10 introns, and participates in the processes of cell cycle regulation, DNA damage repair and induction of apoptosis (<xref rid="b28-etm-0-0-5637" ref-type="bibr">28</xref>,<xref rid="b31-etm-0-0-5637" ref-type="bibr">31</xref>). Normally, the p53 remains the low levels, however, when DNA damaged p53 was overexpressed, which upregulated pro-apoptotic genes, downregulated anti-apoptotic genes through multiple-signaling pathways (<xref rid="b32-etm-0-0-5637" ref-type="bibr">32</xref>). In our study, the p53 expression was significantly increased in berbamine treatment group compared to no berbamine treatment group. The over-expressed p53 may trigger the increased expression of Bax and decreased expression of Bcl-2 in SMMC-7721 cells. Survivin is a recent years discovered anti-apoptotic protein, which participates in the progression and development of malignant tumors (<xref rid="b33-etm-0-0-5637" ref-type="bibr">33</xref>). The survivin inhibits the cell apoptosis by inhibiting apoptotic factors, caspase-3 and &#x2212;7 activity directly (<xref rid="b34-etm-0-0-5637" ref-type="bibr">34</xref>). The present results indicated that berbamine significantly inhibited the survivin mRNA and protein expression in SMMC-7721 cells. The above results suggest that the p53 and survivin play critical role in berbamine triggered apoptosis.</p>
<p>Recent years, there were many studies based on berbamine derivatives have been published. Nam <italic>et al</italic> (<xref rid="b35-etm-0-0-5637" ref-type="bibr">35</xref>) reported that the berbamine derivatives could inhibit the Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Xu <italic>et al</italic> (<xref rid="b36-etm-0-0-5637" ref-type="bibr">36</xref>) showed that the berbamine derivatives affect the Ca<sup>2&#x002B;</sup>-stimulated Mg<sup>2&#x002B;</sup>-dependent ATPase in erythrocyte membranes. Liang <italic>et al</italic> (<xref rid="b37-etm-0-0-5637" ref-type="bibr">37</xref>) reported that 4-chlorbenzoyl berbamine as a novel derivative of berbamine, could inhibit the growth of human myeloma cells by modulating the NF-&#x03BA;B and JNK signaling pathway. Meanwhile, a few previously published studies (<xref rid="b15-etm-0-0-5637" ref-type="bibr">15</xref>,<xref rid="b24-etm-0-0-5637" ref-type="bibr">24</xref>,<xref rid="b25-etm-0-0-5637" ref-type="bibr">25</xref>) also reported the berbamine induced SMMC-7721 cell apoptosis in the other signaling pathways. Wang <italic>et al</italic> (<xref rid="b24-etm-0-0-5637" ref-type="bibr">24</xref>,<xref rid="b25-etm-0-0-5637" ref-type="bibr">25</xref>) proved that the berbamine induced apoptosis was mediated by the mitochondrial transmembrane potential and Fas-mediated mediated signaling pathway. Meng <italic>et al</italic> (<xref rid="b15-etm-0-0-5637" ref-type="bibr">15</xref>) also found that the berbamine induced the apoptosis and inhibited tumor growth by activating Ca<sup>2&#x002B;</sup>/calmodulin-dependent protein kinase II. In the present study, berbamine induced SMMC-7721 cells apoptosis through upregulating p53 expression and downregulating survivin expression, which is distinguish from the above studies (<xref rid="b15-etm-0-0-5637" ref-type="bibr">15</xref>,<xref rid="b24-etm-0-0-5637" ref-type="bibr">24</xref>,<xref rid="b25-etm-0-0-5637" ref-type="bibr">25</xref>).</p>
<p>However, the specific pathways that mediated the role of berbamine have not been fully clarified. Therefore, we thought that the mechanism for the anticancer effects of berbamine in HCC cell lines may also involve many other signaling pathways. In the further studies, we would attempt to investigate the mechanism of action of berberine further by examining the crosstalk between different signaling pathways, such as the p53-dependent signaling pathway, MAPK-survivin signaling pathway and PI3K-Akt pathway.</p>
<p>Totally, the present findings fully proved that the berbamine exhibited higher anticancer activity and trigger-proliferation activity, by activating p53 and survivin expression and triggering the mitochondria signaling pathway. We speculated that interfering the p53 and survivin may control the progression of the HCC. Meanwhile, the extraction process of the berbamine is simple and the price is low. Therefore, the we believed that the present results are significant for clinics.</p>
<p>Although this study received some interesting results, there were also a few limitations. Firstly, the cancer-specific effects of berbamine on the cancer progression has not been fully explored. Secondarily, we have not compared the compound of berbamine to the standard of care, may be there have been a synergistic effect. Thirdly, the extrinsic apoptotic pathway proteins, such as caspase-8 and &#x2212;10, were not examined. Fourthly, the commercially available p53 and survivin inhibitors were not employed to confirm the effect of berbamine on the intrinsic apoptosis signaling pathway in the present study. Fifthly, although the total levels of Cyto <italic>c</italic> was examined, the Cyto <italic>c</italic> transfer from nucleus to cytoplasm has not been observed.</p>
<p>In conclusion, berbamine induced SMMC-7721 cells apoptosis, through upregulating p53 expression and downregulating survivin expression, which further triggers mitochondria signaling pathway mediated apoptosis. In the following researches, we would investigate the molecular mechanisms for berbamine triggered antitumor activity, and evaluate it&#x0027;s security.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was granted by Suzhou People&#x0027;s Livelihood Science and Technology Projects (grant no. SYSD2015151).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-etm-0-0-5637"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><volume>55</volume><fpage>74</fpage><lpage>108</lpage><year>2005</year><pub-id pub-id-type="doi">10.3322/canjclin.55.2.74</pub-id><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref>
<ref id="b2-etm-0-0-5637"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>JM</given-names></name><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Sohn</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Bae</surname><given-names>HI</given-names></name><name><surname>Yun</surname><given-names>YK</given-names></name><name><surname>Hwang</surname><given-names>YJ</given-names></name></person-group><article-title>Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma</article-title><source>J Surg Oncol</source><volume>103</volume><fpage>148</fpage><lpage>151</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/jso.21786</pub-id><pub-id pub-id-type="pmid">21259248</pub-id></element-citation></ref>
<ref id="b3-etm-0-0-5637"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SL</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1</article-title><source>Exp Ther Med</source><volume>9</volume><fpage>579</fpage><lpage>584</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/etm.2014.2137</pub-id><pub-id pub-id-type="pmid">25574238</pub-id></element-citation></ref>
<ref id="b4-etm-0-0-5637"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer statistics, 2009</article-title><source>CA Cancer J Clin</source><volume>59</volume><fpage>225</fpage><lpage>249</lpage><year>2009</year><pub-id pub-id-type="doi">10.3322/caac.20006</pub-id><pub-id pub-id-type="pmid">19474385</pub-id></element-citation></ref>
<ref id="b5-etm-0-0-5637"><label>5</label><element-citation publication-type="journal"><article-title>Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements</article-title><source>J Gastroenterol Hepatol</source><volume>25</volume><fpage>657</fpage><lpage>663</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1440-1746.2009.06167.x</pub-id><pub-id pub-id-type="pmid">20492323</pub-id></element-citation></ref>
<ref id="b6-etm-0-0-5637"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>MF</given-names></name><name><surname>Hou</surname><given-names>JL</given-names></name><name><surname>Chutaputti</surname><given-names>A</given-names></name></person-group><article-title>Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region</article-title><source>J Gastroenterol Hepatol</source><volume>24</volume><fpage>346</fpage><lpage>353</lpage><year>2009</year><pub-id pub-id-type="doi">10.1111/j.1440-1746.2009.05784.x</pub-id><pub-id pub-id-type="pmid">19220670</pub-id></element-citation></ref>
<ref id="b7-etm-0-0-5637"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>LL</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Ruan</surname><given-names>ZP</given-names></name><name><surname>Nan</surname><given-names>KJ</given-names></name></person-group><article-title>Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy</article-title><source>World J Gastroenterol</source><volume>20</volume><fpage>10249</fpage><lpage>10261</lpage><year>2014</year><pub-id pub-id-type="doi">10.3748/wjg.v20.i30.10249</pub-id><pub-id pub-id-type="pmid">25132742</pub-id></element-citation></ref>
<ref id="b8-etm-0-0-5637"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Gea</surname><given-names>V</given-names></name><name><surname>Turon</surname><given-names>F</given-names></name><name><surname>Berzigotti</surname><given-names>A</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name></person-group><article-title>Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension</article-title><source>World J Gastroenterol</source><volume>19</volume><fpage>1193</fpage><lpage>1199</lpage><year>2013</year><pub-id pub-id-type="doi">10.3748/wjg.v19.i8.1193</pub-id><pub-id pub-id-type="pmid">23482437</pub-id></element-citation></ref>
<ref id="b9-etm-0-0-5637"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>KW</given-names></name><name><surname>Sun</surname><given-names>JG</given-names></name><name><surname>Chan</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>SH</given-names></name><name><surname>Fung</surname><given-names>KP</given-names></name><name><surname>Liu</surname><given-names>FY</given-names></name></person-group><article-title>Anticancer effects of imperatorin isolated from <italic>Angelica dahurica</italic>: Induction of apoptosis in HepG2 cells through both death-receptor- and mitochondria-mediated pathways</article-title><source>Chemotherapy</source><volume>57</volume><fpage>449</fpage><lpage>459</lpage><year>2011</year><pub-id pub-id-type="doi">10.1159/000331641</pub-id><pub-id pub-id-type="pmid">22189406</pub-id></element-citation></ref>
<ref id="b10-etm-0-0-5637"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>G</given-names></name></person-group><article-title>Electrospray ionization mass spectrometry probing of binding affinity of berbamine, a flexible cyclic alkaloid from traditional Chinese medicine, with G-quadruplex DNA</article-title><source>Rapid Commun Mass Spectrom</source><volume>28</volume><fpage>143</fpage><lpage>147</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/rcm.6763</pub-id><pub-id pub-id-type="pmid">24285399</pub-id></element-citation></ref>
<ref id="b11-etm-0-0-5637"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>M</given-names></name></person-group><article-title>A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis</article-title><source>Mod Rheumatol</source><volume>20</volume><fpage>238</fpage><lpage>243</lpage><year>2010</year><pub-id pub-id-type="doi">10.3109/s10165-009-0261-2</pub-id><pub-id pub-id-type="pmid">20143119</pub-id></element-citation></ref>
<ref id="b12-etm-0-0-5637"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Perkins</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>RZ</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Horne</surname><given-names>DA</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name></person-group><article-title>Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells</article-title><source>Mol Oncol</source><volume>6</volume><fpage>484</fpage><lpage>493</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.molonc.2012.05.002</pub-id><pub-id pub-id-type="pmid">22717603</pub-id></element-citation></ref>
<ref id="b13-etm-0-0-5637"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Luan</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>E</given-names></name><etal/></person-group><article-title>Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action</article-title><source>Mol Cancer</source><volume>8</volume><fpage>81</fpage><year>2009</year><pub-id pub-id-type="doi">10.1186/1476-4598-8-81</pub-id><pub-id pub-id-type="pmid">19796390</pub-id></element-citation></ref>
<ref id="b14-etm-0-0-5637"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Lou</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Gan</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group><article-title>CaMKII &#x03B3;, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine</article-title><source>Blood</source><volume>120</volume><fpage>4829</fpage><lpage>4839</lpage><year>2012</year><pub-id pub-id-type="doi">10.1182/blood-2012-06-434894</pub-id><pub-id pub-id-type="pmid">23074277</pub-id></element-citation></ref>
<ref id="b15-etm-0-0-5637"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Van Ness</surname><given-names>C</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Lou</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca<sup>2&#x002B;</sup>/calmodulin-dependent protein kinase II</article-title><source>Mol Cancer Ther</source><volume>12</volume><fpage>2067</fpage><lpage>2077</lpage><year>2013</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0314</pub-id><pub-id pub-id-type="pmid">23960096</pub-id></element-citation></ref>
<ref id="b16-etm-0-0-5637"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>FS</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>SG</given-names></name></person-group><article-title>Induction of apoptosis in human hepatoma SMMC-7721 cells by solamargine from <italic>Solanum nigrum</italic> L</article-title><source>J Ethnopharmacol</source><volume>139</volume><fpage>599</fpage><lpage>604</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.jep.2011.11.058</pub-id><pub-id pub-id-type="pmid">22172325</pub-id></element-citation></ref>
<ref id="b17-etm-0-0-5637"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>H</given-names></name><name><surname>Satomi</surname><given-names>Y</given-names></name><name><surname>Tokuda</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name></person-group><article-title>Cancer control by phytochemicals</article-title><source>Curr Pharm Des</source><volume>13</volume><fpage>3394</fpage><lpage>3399</lpage><year>2007</year><pub-id pub-id-type="doi">10.2174/138161207782360519</pub-id><pub-id pub-id-type="pmid">18045193</pub-id></element-citation></ref>
<ref id="b18-etm-0-0-5637"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>XH</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>DM</given-names></name><name><surname>Xiong</surname><given-names>DS</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>CZ</given-names></name><name><surname>Zhu</surname><given-names>HF</given-names></name></person-group><article-title>Effect of calmodulin antagonist O-4-ethoxyl-butyl-berbamine on the proliferation of human breast cancer cell line MCF-7 and its relevant mechanism</article-title><source>Zhongguo Yi Xue Ke Xue Yuan Xue Bao</source><volume>31</volume><fpage>326</fpage><lpage>329</lpage><year>2009</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">19621518</pub-id></element-citation></ref>
<ref id="b19-etm-0-0-5637"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-&#x03B2;/Smad signaling</article-title><source>Anat Rec (Hoboken)</source><volume>297</volume><fpage>802</fpage><lpage>809</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/ar.22897</pub-id><pub-id pub-id-type="pmid">24619961</pub-id></element-citation></ref>
<ref id="b20-etm-0-0-5637"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>ZB</given-names></name><name><surname>Lu</surname><given-names>KJ</given-names></name><name><surname>Wu</surname><given-names>XL</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>XE</given-names></name><name><surname>Yin</surname><given-names>HT</given-names></name></person-group><article-title>In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment</article-title><source>Asian Pac J Cancer Prev</source><volume>15</volume><fpage>1767</fpage><lpage>1769</lpage><year>2014</year><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.4.1767</pub-id><pub-id pub-id-type="pmid">24641406</pub-id></element-citation></ref>
<ref id="b21-etm-0-0-5637"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name></person-group><article-title>Berbamine derivatives: A novel class of compounds for anti-leukemia activity</article-title><source>Eur J Med Chem</source><volume>44</volume><fpage>3293</fpage><lpage>3298</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.ejmech.2009.02.018</pub-id><pub-id pub-id-type="pmid">19285759</pub-id></element-citation></ref>
<ref id="b22-etm-0-0-5637"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>YL</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>XH</given-names></name><name><surname>Zhao</surname><given-names>XY</given-names></name></person-group><article-title>Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo</article-title><source>Acta Pharmacol Sin</source><volume>30</volume><fpage>451</fpage><lpage>457</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/aps.2009.19</pub-id><pub-id pub-id-type="pmid">19270722</pub-id></element-citation></ref>
<ref id="b23-etm-0-0-5637"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia</article-title><source>Int J Hematol</source><volume>94</volume><fpage>156</fpage><lpage>162</lpage><year>2011</year><pub-id pub-id-type="doi">10.1007/s12185-011-0887-7</pub-id><pub-id pub-id-type="pmid">21728004</pub-id></element-citation></ref>
<ref id="b24-etm-0-0-5637"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GY</given-names></name><name><surname>Zhang</surname><given-names>JW</given-names></name><name><surname>L&#x00FC;</surname><given-names>QH</given-names></name><name><surname>Xu</surname><given-names>RZ</given-names></name><name><surname>Dong</surname><given-names>QH</given-names></name></person-group><article-title>Berbamine induces apoptosis in human hepatoma cell line SMMC7721 by loss in mitochondrial transmembrane potential and caspase activation</article-title><source>J Zhejiang Univ Sci B</source><volume>8</volume><fpage>248</fpage><lpage>255</lpage><year>2007</year><pub-id pub-id-type="doi">10.1631/jzus.2007.B0248</pub-id><pub-id pub-id-type="pmid">17444599</pub-id></element-citation></ref>
<ref id="b25-etm-0-0-5637"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GY</given-names></name><name><surname>Lv</surname><given-names>QH</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>RZ</given-names></name><name><surname>Dong</surname><given-names>QH</given-names></name></person-group><article-title>Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice</article-title><source>J Asian Nat Prod Res</source><volume>11</volume><fpage>219</fpage><lpage>228</lpage><year>2009</year><pub-id pub-id-type="doi">10.1080/10286020802675076</pub-id><pub-id pub-id-type="pmid">19408145</pub-id></element-citation></ref>
<ref id="b26-etm-0-0-5637"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dao</surname><given-names>P</given-names></name><name><surname>Jarray</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Lepelletier</surname><given-names>Y</given-names></name><name><surname>Le Coq</surname><given-names>J</given-names></name><name><surname>Lietha</surname><given-names>D</given-names></name><name><surname>Hadj-Slimane</surname><given-names>R</given-names></name><name><surname>Herbeuval</surname><given-names>JP</given-names></name><name><surname>Garbay</surname><given-names>C</given-names></name><name><surname>Raynaud</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities</article-title><source>Cancer Lett</source><volume>348</volume><fpage>88</fpage><lpage>99</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.canlet.2014.03.007</pub-id><pub-id pub-id-type="pmid">24657306</pub-id></element-citation></ref>
<ref id="b27-etm-0-0-5637"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>CE</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Starr</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Horne</surname><given-names>DA</given-names></name><name><surname>Malkas</surname><given-names>LH</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name><name><surname>Hickey</surname><given-names>RJ</given-names></name></person-group><article-title>A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling</article-title><source>PLoS One</source><volume>9</volume><fpage>e94443</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0094443</pub-id><pub-id pub-id-type="pmid">24732116</pub-id></element-citation></ref>
<ref id="b28-etm-0-0-5637"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldar</surname><given-names>S</given-names></name><name><surname>Khaniani</surname><given-names>MS</given-names></name><name><surname>Derakhshan</surname><given-names>SM</given-names></name><name><surname>Baradaran</surname><given-names>B</given-names></name></person-group><article-title>Molecular mechanisms of apoptosis and roles in cancer development and treatment</article-title><source>Asian Pac J Cancer Prev</source><volume>16</volume><fpage>2129</fpage><lpage>2144</lpage><year>2015</year><pub-id pub-id-type="doi">10.7314/APJCP.2015.16.6.2129</pub-id><pub-id pub-id-type="pmid">25824729</pub-id></element-citation></ref>
<ref id="b29-etm-0-0-5637"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>SL</given-names></name><name><surname>Xu</surname><given-names>HP</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>BX</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name></person-group><article-title>Associations of MMP-2, BAX, and Bcl-2 mRNA and protein expressions with development of atrial fibrillation</article-title><source>Med Sci Monit</source><volume>22</volume><fpage>1497</fpage><lpage>1507</lpage><year>2016</year><pub-id pub-id-type="doi">10.12659/MSM.895715</pub-id><pub-id pub-id-type="pmid">27141955</pub-id></element-citation></ref>
<ref id="b30-etm-0-0-5637"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besbes</surname><given-names>S</given-names></name><name><surname>Mirshahi</surname><given-names>M</given-names></name><name><surname>Pocard</surname><given-names>M</given-names></name><name><surname>Billard</surname><given-names>C</given-names></name></person-group><article-title>New dimension in therapeutic targeting of BCL-2 family proteins</article-title><source>Oncotarget</source><volume>6</volume><fpage>12862</fpage><lpage>12871</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.3868</pub-id><pub-id pub-id-type="pmid">25970783</pub-id></element-citation></ref>
<ref id="b31-etm-0-0-5637"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>YP</given-names></name><name><surname>Yuan</surname><given-names>XY</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>DG</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name></person-group><article-title>Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF-&#x03BA;B-p53-caspase-3 pathway</article-title><source>Exp Ther Med</source><volume>9</volume><fpage>1470</fpage><lpage>1476</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/etm.2015.2240</pub-id><pub-id pub-id-type="pmid">25780454</pub-id></element-citation></ref>
<ref id="b32-etm-0-0-5637"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Xia</surname><given-names>D</given-names></name></person-group><article-title>Effect of mir-122 on human cholangiocarcinoma proliferation, invasion, and apoptosis through P53 expression</article-title><source>Med Sci Monit</source><volume>22</volume><fpage>2685</fpage><lpage>2690</lpage><year>2016</year><pub-id pub-id-type="doi">10.12659/MSM.896404</pub-id><pub-id pub-id-type="pmid">27472451</pub-id></element-citation></ref>
<ref id="b33-etm-0-0-5637"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Survivin - The inconvenient IAP</article-title><source>Semin Cell Dev Biol</source><volume>39</volume><fpage>91</fpage><lpage>96</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.semcdb.2014.12.007</pub-id><pub-id pub-id-type="pmid">25591986</pub-id></element-citation></ref>
<ref id="b34-etm-0-0-5637"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention</article-title><source>Mol Clin Oncol</source><volume>1</volume><fpage>215</fpage><lpage>219</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/mco.2012.36</pub-id><pub-id pub-id-type="pmid">24649149</pub-id></element-citation></ref>
<ref id="b35-etm-0-0-5637"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Perkins</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>RZ</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Home</surname><given-names>DA</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name></person-group><article-title>Novel synthetic derivatives of the natural product berbamine inhibit Jak/Stat3 signaling and induce apoptosis of human melanoma cells</article-title><source>Mol Oncol</source><volume>6</volume><fpage>484</fpage><lpage>493</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.molonc.2012.05.002</pub-id><pub-id pub-id-type="pmid">22717603</pub-id></element-citation></ref>
<ref id="b36-etm-0-0-5637"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>YH</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>SP</given-names></name><name><surname>Liu</surname><given-names>LH</given-names></name></person-group><article-title>The effect of berbamine derivatives on Ca<sup>2&#x002B;</sup>-stimulated Mg<sup>2&#x002B;</sup>-dependent ATPase in erythrocyte membranes</article-title><source>Biochem J</source><volume>248</volume><fpage>985</fpage><lpage>988</lpage><year>1987</year><pub-id pub-id-type="doi">10.1042/bj2480985</pub-id><pub-id pub-id-type="pmid">2963623</pub-id></element-citation></ref>
<ref id="b37-etm-0-0-5637"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name></person-group><article-title>4-Chlorbenzoyl berbamine, a novel derivative of the natural product berbamine, potently inhibits the growth of human myeloma cells by modulating the NF-&#x03BA;B and JNK signalling pathways</article-title><source>Cancer Invest</source><volume>34</volume><fpage>496</fpage><lpage>505</lpage><year>2016</year><pub-id pub-id-type="doi">10.1080/07357907.2016.1235709</pub-id><pub-id pub-id-type="pmid">27768381</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-etm-0-0-5637" position="float">
<label>Figure 1.</label>
<caption><p>Observation for the IC<sub>50</sub> and cell viability. (A) IC<sub>50</sub> examination. &#x002A;&#x002A;P&#x003C;0.05 represents the IC<sub>50</sub> in SMMC-7721 group compared to normal hepatocyte group. (B) Cell viability was examined by using MTT assay. &#x002A;P&#x003C;0.05 represents the cell viability compared to control group. <sup>#</sup>P&#x003C;0.05 represents the cell viability compared to 10 &#x00B5;mol/l berbamine. <sup>&#x0026;</sup>P&#x003C;0.05 represents the cell viability compared to 20 &#x00B5;mol/l berbamine.</p></caption>
<graphic xlink:href="etm-15-02-1894-g00.jpg"/>
</fig>
<fig id="f2-etm-0-0-5637" position="float">
<label>Figure 2.</label>
<caption><p>Cell morphology observation for SMMC-7721 cells under inverted microscope (magnification, &#x00D7;200). (A) Control group; (B) 10 &#x00B5;mol/l berbamine; (C) 20 &#x00B5;mol/l berbamine; and (D) 40 &#x00B5;mol/l berbamine.</p></caption>
<graphic xlink:href="etm-15-02-1894-g01.jpg"/>
</fig>
<fig id="f3-etm-0-0-5637" position="float">
<label>Figure 3.</label>
<caption><p>DAPI staining for SMMC-7721 cell nucleus observed under immunofluorescence microscope (magnification, &#x00D7;200). (A) Control group; (B) 10 &#x00B5;mol/l berbamine; (C) 20 &#x00B5;mol/l berbamine; (D) 40 &#x00B5;mol/l berbamine. The light stained cells represent the DAPI positively stained cells.</p></caption>
<graphic xlink:href="etm-15-02-1894-g02.jpg"/>
</fig>
<fig id="f4-etm-0-0-5637" position="float">
<label>Figure 4.</label>
<caption><p>Observation for the Berbamine induced SMMC-7721 cell apoptosis by using flow cytometry assay. (A) Images for flow cytometry assay in every groups. (B) Statistical analysis for flow cytometry assay. Q1 quadrant represents the living cells; Q2 quadrant represents the early apoptosis cells; Q3 quadrant represents the late apoptosis cells; and Q4 quadrant represents the death cells. The apoptosis rate was composed of percentage of Q1 plus Q2. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 represent apoptosis rate compared to the control group.</p></caption>
<graphic xlink:href="etm-15-02-1894-g03.jpg"/>
</fig>
<fig id="f5-etm-0-0-5637" position="float">
<label>Figure 5.</label>
<caption><p>Examination for the Cyto C expression by using immunofluorescence assay at 48 h post berbamine treatment (magnification, &#x00D7;200). The green fluorescence illustrates Cyto C staining, the blue fluorescence illustrates DAPI staining, the merged images are the Ctyo C and DAPI double stained SMMC-7721 cells.</p></caption>
<graphic xlink:href="etm-15-02-1894-g04.jpg"/>
</fig>
<fig id="f6-etm-0-0-5637" position="float">
<label>Figure 6.</label>
<caption><p>RT-sqPCR examination for the apoptosis associated genes in berbamine treated SMMC-7721 cells. (A) RT-sqPCR bands for the Bax, Bcl-2, p53 and survivin mRNA expression. (B) Statistical analysis for the mRNA expression. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 represent the mRNA expression compared to the control group. The data are presented as the mean &#x00B1; standard deviation (n=6).</p></caption>
<graphic xlink:href="etm-15-02-1894-g05.jpg"/>
</fig>
<fig id="f7-etm-0-0-5637" position="float">
<label>Figure 7.</label>
<caption><p>Western blot analysis examination for apoptosis associated proteins in berbamine treated SMMC-7721 cells. (A) Western blot bands for Bax, Bcl-2, p53 and survivin protein expression. (B) Statistical analysis for the protein expression. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 represent the protein expression compared to the control group. The data are presented as the mean &#x00B1; standard deviation (n=6).</p></caption>
<graphic xlink:href="etm-15-02-1894-g06.jpg"/>
</fig>
<table-wrap id="tI-etm-0-0-5637" position="float">
<label>Table I.</label>
<caption><p>Sequence of the primers used for reverse transcription-semi-quantitative polymerase chain reaction.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Genes</th>
<th align="center" valign="bottom">Sequence (5&#x2032;-3&#x2032;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Bax</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Forward</td>
<td align="left" valign="top">GCTCTGAGCAGATCATGAAG</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Reverse</td>
<td align="left" valign="top">CAAAGTAGAAAAGGGCGACA</td>
</tr>
<tr>
<td align="left" valign="top">Bcl-2</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Forward</td>
<td align="left" valign="top">CCGGGAGATAGTGATGAAGT</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Reverse</td>
<td align="left" valign="top">ACTCAAAGAAGGCCACAATC</td>
</tr>
<tr>
<td align="left" valign="top">p53</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Forward</td>
<td align="left" valign="top">ACATGTGTAACAGTTCCTGC</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Reverse</td>
<td align="left" valign="top">TCCATCCAGTGGTTTCTTCT</td>
</tr>
<tr>
<td align="left" valign="top">Survivin</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Forward</td>
<td align="left" valign="top">CCAGTGTTTCTTCTGCTTCA</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Reverse</td>
<td align="left" valign="top">CGCACTTTCTTCACAGTTTC</td>
</tr>
<tr>
<td align="left" valign="top">GAPDH</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Forward</td>
<td align="left" valign="top">AAGATCATCAGCAATGCCTC</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Reverse</td>
<td align="left" valign="top">TTGGCAGGTTTTTCTAGACG</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-etm-0-0-5637"><p>Bcl-2, B-cell lymphoma-2; Bax, Bcl-2 associated X, apoptosis regulator.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
